Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that will make the kidney disease drug developer the first U.S. biotech ...
The Mesoblast Ltd (ASX: MSB) share price is charging higher today. Again. Shares in the S&P/ASX 300 Index (ASX: XKO) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback